Fig. 8
From: Migrasome-related LncRNA features predict immune microenvironment and prognosis in pancreatic cancer
The sensitivity of pancreatic cancer to ten drugs. (a) The distribution of IC50 values shows a significant difference between patients in the low-group and high-risk group among Buparlisib, Rapamycinm, AZD8055, AZD2014, and AZD6482. (b) The distribution of IC50 values shows a significant difference between patients in the low-group and high-risk group among Doramapimod, SCH772984, Trametinib, VX-11e and CDK inhibitor Dinaciclib.
